Sign Up for a Free Account
  • Updated 10.07.2021
  • Released 07.06.1999
  • Expires For CME 10.07.2024

Ropinirole

Introduction

Historical note and terminology

Ropinirole is a second-generation dopamine agonist. Dopamine agonists were first used in patients with moderate or advanced Parkinson disease. There is now a tendency to introduce dopamine agonists in the first stages of the disease as an attempt to delay motor fluctuations. Although many dopamine agonists were developed, only four were marketed and are used extensively for the treatment of Parkinson disease: apomorphine, bromocriptine, lisuride, and pergolide. Ropinirole is one of three newer dopamine agonists; the other two are cabergoline and pramipexole. Ropinirole hydrochloride was developed as SKF-101468A and was shown to have antiparkinsonian effects in primate MPTP models of parkinsonism (04). The United States Food and Drug Administration approved it in 1997 for the treatment of Parkinson disease.

This is an article preview.
Start a Free Account
to access the full version.

  • Nearly 3,000 illustrations, including video clips of neurologic disorders.

  • Every article is reviewed by our esteemed Editorial Board for accuracy and currency.

  • Full spectrum of neurology in 1,200 comprehensive articles.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125